Imvax Announces Completion of $29 Million Financing and Confirms Timing for Topline Results of Phase 2b Trial of IGV-001 in Newly Diagnosed Glioblastoma
– Financing funds operations into 2026 – – Company on track to report topline results from Phase 2b trial of IGV-001 in mid-2025 – January 29, 2025 07:00 AM Eastern Standard Time PHILADELPHIA–(BUSINESS WIRE)–Imvax, Inc.,…